Pharmaceutical formulations

Abstract

The present invention provides a novel pharmaceutical formulation comprising (a) compound of Formula (1) wherein R1 is halo, cyano, optionally substituted lower alkyl, or optionally substituted lower alkoxyl; and R2 is optionally substituted aryl, or optionally substituted heterocyclyl; or a prodrug; (b) at least one diluent or filler; (c) optionally at least one disintegrant; (d) optionally at least one binder; and (e) optionally at least one lubricant; wherein the compound of formula (I) is present in an amount within the range of from about 1% to about 80% by weight; the diluent or filler is present in an amount within the range of from about 10% to about 95% by weight; the disintegrant, if present, is present in an amount within the range of from about 0.1% to about 20% by weight; the binder, if present, is present in an amount within the range of from about 0.1% to about 20% by weight; and the lubricant, if present, is present in an amount within the range of from about 0.1 % to about 5% by weight, all of the above % by weight being based on the weight of the formulation. In its many embodiments, the present invention also provides prevention, inhibition or amelioration of one or more diseases associated with sodium-dependent glucose transporter using such pharmaceutical compositions.